GLP

News • Pharma

Lilly to Build $6.5 Billion US Pharmaceutical Plant

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.

News

Novo Nordisk Invests $1.09 Billion in Brazil

Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.

News

Reaction Biology Buys Germany’s Bioassay

US contract research organization Reaction Biology has acquired German contract laboratory Bioassay Labor für biologische Analytik and its wholly owned subsidiary Peptide Specialty Laboratories (PSL).

Top-Feature

Sasol

Industry Kick-Off with Signal Effect: More Than 310 Exhibitors expected at maintenance and PUMPS & VALVES 2026

Together for Sustanability (TFS)

Driving Sustainability Through Collaboration

Interview

The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Eli Lilly and Company

Novo Nordisk A/S

GLP

Lilly to Build $6.5 Billion US Pharmaceutical Plant

Novo Nordisk Invests $1.09 Billion in Brazil

Reaction Biology Buys Germany’s Bioassay

Top-Feature

Leading Transformation

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Anchored in Sustainability

Leading the way. Driving results.

Brenntag Downsizes Management Board, Retains Both Divisions

API Manufacturing

Advanced Recycling Conference 2025: New Paths to the Circular Economy

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Europe’s Biotech Inflection Point

Industry Kick-Off with Signal Effect: More Than 310 Exhibitors expected at maintenance and PUMPS & VALVES 2026

Driving Sustainability Through Collaboration

Interview

Leading Transformation

Newsletter & e-edition